Use of glitazones in cardiac patients: A case for B-type natriuretic peptide monitoring?

American Journal of Cardiology

Volumn 93, Issue 5, 2004, Pages 600-602

  El Muayed, Malek ^a,b   Lavis, Victor R ^a   Safi, Hazim J ^a   Fuentes, Francisco ^a  

^a C AND EN   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BRAIN NATRIURETIC PEPTIDE; GLUCOSE; INSULIN SENSITIZING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE;

BIOLOGICAL MONITORING; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; EDITORIAL; GLUCOSE BLOOD LEVEL; HEALTH STATISTICS; HEART PROTECTION; HUMAN; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; RECEPTOR AFFINITY; SIDE EFFECT; UNITED STATES;

EID: 1442348776     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.11.025     Document Type: Note

References (30)

1. Asakawa M., Takano H., Nagai T., Uozumi H., Hasegawa H., Kubota N., Saito T., Masuda Y., Kadowaki T., Komuro I. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 105:2002;1240-1246.
2. Yamamoto K., Ohki R., Lee R.T., Ikeda U., Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation. 104:2001;1670-1675.
3. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 129:2000;823-834.
4. Takano H., Nagai T., Asakawa M., Toyozaki T., Oka T., Komuro I., Saito T., Masuda Y. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res. 87:2000;596-602.
5. Stumvoll M., Haring H. Glitazones clinical effects and molecular mechanisms. Ann Med. 34:2002;217-224.
6. Oakes N.D., Thalen P.G., Jacinto S.M., Ljung B. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes. 50:2001;1158-1165.
7. Smith U., Gogg S., Johansson A., Olausson T., Rotter V., Svalstedt B. Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J. 15:2001;215-220.
8. Wu Z., Xie Y., Morrison R.F., Bucher N.L.R., Farmer S.R. PPAR gamma induces the insulin-dependent glucose transporter GLUT4 in absence of S/EBPa during the conversion of 3T3 fibroblasts into adipocytes. J Clin Invest. 101:1998;22-32.
9. Finegood D.T., McArthur M.D., Kojwang D., Thomas M.J., Topp B.G., Leonard T., Buckingham R.E. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes. 50:2001;1021-1029.
10. Szalkowski D., White-Carrington S., Berger J., Zhang B. Antidiabetic thiazolidinediones block the inhibitory effects of TNFα on differentiation, insulin stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology. 136:1995;1474-1481.
11. Hofmann C., Lorenz K., Braithewaite S.S., Colca J.R., Palazuk B.J. Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance. Endocrinology. 134:1994;264-270.
12. Hotamisligil G.S., Sargill N.S., Spiegelmann B.M. Adipose tissue expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 259:1993;87-91.
13. Ghazzi M.N., Perez J.E., Antonucci T.K., Driscoll J.H., Huang S.M., Faja B.W., Whitcomb R.W., The Troglitazone Study Group. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes. 46:1997;433-439.
14. Sugawara A., Takeuchi K., Uruno A., Ikeda Y., Arima S., Sato K., Kudo M., Taniyama Y., Ito S. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertens Res. 24:2001;229-233.
15. Bryant D., Becker L., Richardson J., Shelton J., Franco F., Peshock R., Thompson M., Giroir B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation. 97:1998;1375-1381.
16. Takata Y., Kitami Y., Yang Z.H., Nakamura M., Okura T., Hiwada K. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma. Circ Res. 691:2002;427-433.
17. Niemeyer N.V., Janney L.M. Thiazolidinedione-induced edema. Pharmacotherapy. 22:2002;924-929.
18. Thomas M.L., Lloyd S.J. Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother. 35:2001;123-124.
19. Wang C.H., Weisel R.D., Liu P.P., Fedak P.W.M., Verma S. Glitazones and heart failure critical appraisal for the clinician. Circulation. 107:2003;1350-1354.
20. Donnelly R, Gray S, Idris I. Rosiglitazone and ankle swelling: an acute dose-dependent effect on endothelial permability. Diabetes 2001;50:A68
21. Sakai S., Miyauchi T., Irukayama-Tomobe Y., Ogata T., Goto K., Yamaguchi I. Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. Clin Sci. 103:(suppl): 2002;16S-20S.
22. Logeart D., Saudubray C., Beyne P., Thabut G., Ennezat P.V., Chavelas C., Zanker C., Bouvier E., Solal A. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol. 2040:2002;1794-1800.
23. McCullough P.A., Nowak R.M., McCord J., Hollander J.E., Herrmann H.C., Steg P.G., Duc P., Westheim A., Omland T., Knudsen C.W., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 23106:2002;416-422.
24. Lubien E., DeMaria A., Krishnaswamy P., Clopton P., Koon J., Kazanegra R., Gardetto N., Wanner E., Maisel A.S. Utility of B-natriuretic peptide in detecting diastolic dysfunction comparison with Doppler velocity recordings. Circulation. 5105:2002;595-601.
25. Haug C., Metzele A., Kochs M., Hombach V., Grunert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol. 16:1993;553-557.
26. Wieczorek S.J., Wu A.H., Christenson R., Krishnaswamy P., Gottlieb S., Rosano T., Hager D., Gardetto N., Chiu A., Bailly K.R., Maisel A. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure a multicenter evaluation. Am Heart J. 144:2002;834-839.
27. Lang C.C., Coutie W.J., Khong T.K., Choy A.M., Struthers A.D. Dietary sodium loading increases plasma brain natriuretic peptide levels in man. J Hypertens. 9:1991;779-782.
28. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 355:2000;1126-1130.
29. Gurnell M., Savage D., Chatterjee V., O'Rahilly S. The metabolic syndrome peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab. 88:2003;2412-2421.
30. Ogawa S., Takeuchi K., Ito S. Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J Clin Endocrinol Metab. 88:2003;3993-3996.